Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Schering to globalize clinical trial management

Executive Summary

Schering-Plough plans to globalize its clinical trial operations as part of its action agenda initiated in 2003 which seeks to transform the company into a high-performance competitor. Schering expects its Global Clinical Harmonization program will ensure better planning, prioritization, consistency and, as a result, improve efficiencies. One change will see the integration of Phase IV studies under the same roof as earlier development areas. Schering announced that it entered the "turnaround" phase of its action agenda late last year (1"The Pink Sheet" Nov. 7, 2005, p. 18). The globalization of clinical trial activities is not expected to result in head-count reductions...

You may also be interested in...

Schering Seeks Salvation In External Deals; Hassan Outlines Licensing Plan

The solution to the "innovation threat" facing big pharma lies in making deals outside the company, Schering-Plough CEO Fred Hassan said during an R&D update Nov. 1

Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast episode of Five Must-Know Things, hear about issues surrounding the proposed IP waiver for coronavirus vaccines, a trial delay for Novavax’s COVID-19 vaccine, an ICER review of multiple myeloma drugs and Galapagos’ efforts to refocus its R&D pipeline.

Finance Watch: Four Biotech VC Funds Raise $1.7bn Combined

Private Company Edition: Perceptive/Xontogeny, Abingworth, Kizoo and Droia closed venture capital funds. New biopharma VC financings also include a $105m series C round for Elpiscience and $92m for newly launched Interline. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts